active disease. A higher percentage of patients receiving epratuzumab 1200mg EOW, compared with placebo, had an improvement in baseline BILAG A/B scores to BILAG C or D in musculoskeletal, mucocutaneous, neuropsychiatric, and renal systems. In the cardiorespiratory system, all 7 patients in the epratuzumab 600mg weekly group had improved to a BILAG D at Week 12. Similarly, in the neuropsychiatric system, 5 out of 6 patients in the epratuzumab 600mg weekly group improved from BILAG B at baseline to BILAG D at Week 12.
About systemic lupus erythematosus (SLE)SLE, commonly referred to as lupus, is a chronic and potentially fatal autoimmune disease with a variable and unpredictable course. Antibodies are generated against the body's own nuclear proteins causing the immune system to attack its own cells and tissues resulting in inflammation and tissue damage. This can occur in any part of the body, but most often targets the heart, joints, skin, lungs, blood vessels, liver, kidneys and nervous system.
Lupus is characterized by periods of flares, or exacerbations, interspersed with periods of improvement or remission. The Lupus Foundation of America estimated that between 1.5-2 million Americans have a form of lupus, 90 percent of whom are women. Symptoms and diagnosis occur most often between the ages of 15 and 45. In the U.S., lupus is more common in African Americans, Latinos, Asians, and Native Americans than in Caucasians.
About UCBUCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With more than 8 000 people in about 40 countries, the company generated revenue of EUR 3.1 billion in 2009. UCB is listed on Euronext Brussels (symbol: UCB).
Page: 1 2 3 4 5 6 7 Related medicine technology :1
. Study Results Show Epratuzumab Provided Clinically Meaningful Reduced Disease Activity in Patients With Lupus2
. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients3
. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline4
. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-885
. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma6
. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML7
. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor8
. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet9
. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-79610
. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)11
. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947